The quarter beat the only published earnings benchmark, but the comparison is unusually noisy. Scribe reported a $2.62 basic and diluted per-share loss versus a published consensus loss of about $6.20, a sizable headline beat. The filing does not provide company guidance, and the smaller reported loss was helped by a $3.0 million gain from the fair value change in its convertible note, so the EPS outperformance says less about underlying operating momentum than the headline suggests. (Statement of Operations)
| Metric | Q2 2026 | Q2 2025 | External expectation |
|---|---|---|---|
| Collaboration revenue | $1.918M (Statement of Operations) | $4.898M (Statement of Operations) | ~$3.11M published consensus |
| Net loss | $6.477M (Statement of Operations) | $9.903M (Statement of Operations) | — |
| Basic and diluted loss per share | $2.62 (Financial Results) | $4.08 (Financial Results) | ~$6.20 loss consensus |
| Research and development expense | $8.823M (Statement of Operations) | $13.884M (Statement of Operations) | — |
| Cash, cash equivalents and investments | $43.009M (Selected Balance Sheet Items) | $57.963M at Dec. 31, 2025 (Selected Balance Sheet Items) | — |
Revenue was the clear operating miss. Collaboration revenue fell to $1.9 million from $4.9 million a year earlier and was below the roughly $3.1 million published quarterly expectation. The company attributes the decline to lower reimbursable research activity and reduced revenue recognition, which makes the result less alarming than a demand collapse but still leaves Scribe with no commercial revenue engine to offset clinical spending.
The substantive positive change is financing and pipeline execution, not the quarter's P&L. Scribe started the first-in-human Phase 1 trial for STX-1150, received approximately $25.7 million in non-dilutive CIRM grants for STX-1200 and STX-1400, and raised approximately $140.6 million net in its July IPO and private placement. 〔0〕 These developments materially reduce near-term financing pressure, with management projecting funding into the first half of 2029, though the IPO and listing were already public before this filing and therefore are not wholly new information.
Net read: a narrow earnings beat, with the market's real test deferred to clinical data. The filing improves funding visibility and advances STX-1150 into the clinic, but collaboration revenue missed, the EPS beat benefited from a non-operating accounting gain, and all efficacy evidence remains preclinical. The next decisive milestone is initial Phase 1 safety, tolerability, and LDL-C activity data expected in the first half of 2027. 〔1〕
Read the original 8-K on SEC EDGAR ↗